Key Stats
52-Week Range
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
Choose a result to open the company. Use arrow keys to choose a result and Enter to confirm.
#51 ๐บ๐ธ US
OTC Markets OTCPKยทNVSEF
$152.0000
โฌ138.52
-2.88% (24h)
Market Cap
$287.07B
โฌ261.61B
Volume (24h)
200 shrsยท $30.4K
โฌ27.70K
Last Close (7D)
$152.00
โฌ138.52
Prices in USD. No currency conversion.
52-Week Range
Estimates and expected reporting dates may change.
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure; Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis
Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6; Promacta/Revolade for immune thrombocytopenia (ITP), thrombocytopenia, and aplastic anemia patients Tafinlar+Mekinist, an oral combination therapy to treat cancer patients; and Jakavi for treating myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease.
It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in chronic and/or accelerated phase; Xolair for treating allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps
Ilaris to treat fever syndromes, Stills disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer
Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma to treat genetic root cause of spinal muscular atrophy
Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology.
It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran) to reduce LDL cholesterol. Novartis AG has a strategic alliance with CAS for enhancing reaction data accessibility and supporting AI-enabled research. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Foreign current report
Explained the issuance by Novartis Capital Corporation of $500 million of 4.900% notes due 2029, $1.5 billion of 5.200% notes due 2032 and further notes.
6-K
2026-11-12
SEC
Prospectus supplement
Filed a prospectus supplement on November 10, 2026 for Novartis Capital Corporation notes, including $500 million of 4.900% notes due 2029 and $1.5 billion of 5.200% notes due 2032.
424B5
2026-11-10
SEC
Prospectus supplement
Filed a preliminary prospectus supplement for Novartis Capital Corporation notes due 2029 and 2032, among other maturities, dated November 9, 2026.
424B5
2026-11-09
SEC
Foreign current report
Furnished a Form 6-K on October 27, 2026 including an R&D update on key developments from the first quarter, incorporated by reference into S-8 registration statements.
6-K
2026-10-27
SEC
Foreign current report
Announced that the Phase III HARBOR study of del-desiran in myotonic dystrophy type 1 did not meet its primary endpoint of vHOT.
6-K
2026-09-08
SEC
Foreign current report
Announced Phase III Lp(a)HORIZON topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease, on September 4, 2026.
6-K
2026-09-04
SEC
Foreign current report
Announced that Phase III REMODEL-1/-2 trials of remibrutinib in relapsing multiple sclerosis met their primary endpoint of reducing annualized relapse rates.
6-K
2026-09-01
SEC
Foreign current report
Furnished a Form 6-K on July 21, 2026 including an R&D update on key developments from the second quarter, incorporated by reference into S-8 registration statements.
6-K
2026-07-21
SEC
Foreign current report
Announced that the Phase I/II FORTITUDE study of del-brax in facioscapulohumeral muscular dystrophy met its primary biomarker endpoint.
6-K
2026-06-11
SEC
Foreign current report
Furnished a Form 6-K on April 28, 2026 including an R&D update on key developments from the first quarter, incorporated by reference into S-8 registration statements.
6-K
2026-04-28
SEC
Yahoo ยท Nov 20, 2026
Sector Update: Healthcare Stocks Rise Late Afternoon
Yahoo ยท Nov 20, 2026
Sector Update: Healthcare Stocks Rise Friday Afternoon
Yahoo ยท Nov 20, 2026
AstraZeneca leads European big pharma on growth, pipeline depth
Yahoo ยท Nov 20, 2026
Market Chatter: Novartis CEO Says US Limits on China Biotech Investment May Hurt Drug Development
Yahoo ยท Nov 20, 2026
Novartis CEO: AI Could Cut Drug Development Time by Years
SeekingAlpha ยท Nov 20, 2026
Biogen: Why I'm Still Bullish Despite Market Turmoil
Americas
Europe
Asia